An advisory panel for the Food and Drug Administration voted on Friday to recommend authorizing booster shots for Johnson & Johnson's COVID-19 vaccine.
The recommendation, which is for people ages 18 and up, suggests boosters at least two months after the initial dose. As some experts view it, the vote essentially changes the Johnson & Johnson vaccine from a "one and done" single dose immunization into something closer to the two-shot regimen created by Moderna and Pfizer. "Many members of the [FDA] panel said that a second dose was important because the first dose did not provide strong enough protection," writes The New York Times. The J&J vaccine has slightly lower efficacy than the other two approved for use in the U.S., but has so far continued to successfully prevent most serious illness or hospitalization among recipients.
The panel's vote isn't particularly surprising, since many experts have predicted that boosters would likely be approved to ward against waning immunity, but Stat News' Helen Branswell still reported that "this [turned] out to be a bad meeting for J&J," arguing that it's a bad look for Johnson & Johnson that so many FDA panelists believe the vaccine should become a two-dose regimen. The panel opted to recommend boosters sooner than J&J's suggested 6-month gap between doses.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"I think this frankly was always a two-dose vaccine," said panelist Paul Offitt, an infectious disease expert at the Children's Hospital of Philadelphia. "It's hard to recommend this as a one-dose vaccine."
Though J&J isn't changing its vaccine authorization to now be considered a two-dose vaccine, that's essentially what the panel thinks it should become. Panelist Eric Rubin, editor-in-chief of The New England Journal of Medicine, said J&J should be asking for a universal booster dose at two months. "He didn't use the term, but that's a two-dose vaccine," writes Branswell.
The other aspect of the meeting that doesn't bode well for Johnson & Johnson is that the panel is considering whether to recommend that J&J recipients get a booster from a different company. A vote on that issue will come later. Either way, as health reporters note, the fact that the FDA panel shot down J&J's argument that its COVID-19 vaccine could continue as a single-shot dose with a long gap between the initial jab and an eventual booster is a blow to both the company and Americans who benefited from a "one and done."
-
What to know before turning to AI for financial advicethe explainer It can help you crunch the numbers — but it might also pocket your data
-
Book reviews: 'The Headache: The Science of a Most Confounding Affliction—and a Search for Relief' and 'Tonight in Jungleland: The Making of Born to Run'Feature The search for a headache cure and revisiting Springsteen's 'Born to Run' album on its 50th anniversary
-
Keith McNally' 6 favorite books that have ambitious charactersFeature The London-born restaurateur recommends works by Leo Tolstoy, John le Carré, and more
-
Rabbits with 'horns' sighted across Coloradospeed read These creatures are infected with the 'mostly harmless' Shope papilloma virus
-
Lithium shows promise in Alzheimer's studySpeed Read Potential new treatments could use small amounts of the common metal
-
Scientists discover cause of massive sea star die-offSpeed Read A bacteria related to cholera has been found responsible for the deaths of more than 5 billion sea stars
-
'Thriving' ecosystem found 30,000 feet underseaSpeed Read Researchers discovered communities of creatures living in frigid, pitch-black waters under high pressure
-
New York plans first nuclear plant in 36 yearsSpeed Read The plant, to be constructed somewhere in upstate New York, will produce enough energy to power a million homes
-
Dehorning rhinos sharply cuts poaching, study findsSpeed Read The painless procedure may be an effective way to reduce the widespread poaching of rhinoceroses
-
Breakthrough gene-editing treatment saves babyspeed read KJ Muldoon was healed from a rare genetic condition
-
Sea lion proves animals can keep a beatspeed read A sea lion named Ronan beat a group of college students in a rhythmic dance-off, says new study
